New collaborations pairing drug makers with insurers, health systems, patient groups and technology firms are reconfiguring drug R&D and commercialization. Shared data is shaping drug development anddemonstrating health outcomes to create value for patients and industry.
Ten years after HRI began issuing projections, challenges remain despite improvements in efficiency and quality that have begun to bend the cost curve. Much of the slowing growth can be attributable to cost shifting. Consumers, who consequently bear more decision-making on health services, are looking for greater value.
Since 2010, the Affordable Care Act has underscored the rise of a New Health Economy predicated on value. Here are five fundamental shifts the law has energized over the past five years and how they will continue to shape the healthcare industry in the next five.
Pharmaceutical and life science companies and their chief regulator – the FDA – must find new ways to collaborate to meet 21st century demands. A modern regulatory framework is needed to ensure America’s global lead in innovation and stimulate the next generation of treatments and cures.
Technology companies are developing a myriad of wearable health devices that can track physical activity, monitor glucose and even sense if the user falls. What do consumers think about wearables? What are the implications for the health industry?